Travere Therapeutics recently received accelerated approval for Filspari (sparsentan) for the treatment of IgA Nephropathy (IgAN) and raised $200 million in a public offering. The company may struggle ...
U.S. net product sales of FILSPARI ® (sparsentan) grew 155% year-over-year to $90.9 million in 3Q 2025; 731 new PSFs received during the quarter Total revenue for 3Q 2025 was $164.9 million, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results